
Opinion|Videos|December 25, 2024
Exploring Second-Line Treatments for PBC
Panelists discuss how some patients with primary biliary cholangitis (PBC) have an inadequate response to ursodeoxycholic acid and require second-line treatments, with options including obeticholic acid, seladelpar, and elafibranor, which improve bile acid homeostasis and reduce inflammation.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- How often do patients require second-line treatments for PBC, and what agents are available for second-line management?
- How do the mechanisms of action differ between seladelpar, elafibranor, and obeticholic acid?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Medicare Is Finally Covering GLP-1s for Weight Loss: What the Bridge Program Means for Your Practice
2
Updated 2025-2026 COVID-19 Vaccine Nearly Halved ED Visits, Hospitalizations in CDC-Funded Study
3
FDA Narrows Compounding Rules for GLP-1s: How Pharmacists Should Respond
4
The Biosimilar Conversation Nobody Is Having at the Pharmacy Counter: Why Adoption Is Still Struggling and What We Can Do About It
5

















































































































